TrialBreast cancer research and treatment2023

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).

Kokoro Kobayashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.